USA-based Integrated Manufacturing Facility
Expertise From Clinical to Commercial Scale
Complete Regulatory Compliance & Documentation
End-To-End Manufacturing Under One Roof
Rapid, Reliable Tech Transfer
75 years of Pharmaceutical Manufacturing Excellence
Lannett CDMO offers a strategic advantage for businesses aiming to bring anti-obesity medications like semaglutide to market more efficiently, primarily due to our expertise, experience and production capacity.
Our unwavering commitment to quality assurance ensures that every product we manufacture meets the highest standards of safety and efficacy, providing peace of mind to our partners and their end-users.
Rapid prototyping is a key feature of our approach. With our expertise as a pharmaceutical CDMO, we collaborate with trusted partners to support their product development process and substantially reduce time-to-market. Our scalable manufacturing capabilities also allow us to adjust production levels swiftly to meet demand and provide continuity of supply.
Lannett CDMO’s regulatory expertise plays a crucial role in guiding our partners through the often-complex regulatory approval process, providing essential support at every step. Beyond this, we maintain strong partnerships with regulatory authorities to facilitate smooth and timely regulatory approvals.
By partnering with Lannett CDMO, pharmaceutical companies can leverage our expertise to accelerate their timelines for bringing innovative semaglutide weight loss OSDs to market.
Lannett’s CDMO services demonstrate a strong capability in manufacturing high quality Oral Solid Dose (OSD) products through several key factors:
Specialized contract manufacturing of OSDs, including high potency substances and small molecules.
224,000 square feet dedicated to production facilities and an additional 204,000 square feet for warehousing and distribution.
Extensive experience as a trusted provider of high-quality pharmaceuticals in the industry, dating back to 1942.
Scalable operations to meet effectively increasing demand while maintaining stringent quality standards.
World-class manufacturing facilities equipped to handle the complete manufacturing process and commercial supply to efficiently meet diverse client needs.
Strict adherence to regulatory standards, including ICH Q8, Q10, and FDA cGMP compliance to meet high safety and efficacy requirements.
High production capacity, manufacturing approximately 3.5 billion oral solid doses annually.
Robust quality assurance processes, operational efficiency and reliability contribute to a consistent average product yield rate of 96%.
Lannett CDMO also offers tech transfer services that streamline the transition from product development to manufacturing, further enhancing efficiency and responsiveness to client needs.
Overall, this combination of extensive experience, advanced facilities, regulatory compliance, and commitment to quality positions us as a leading CDMO of oral solid dosage forms (OSDs) for obesity treatment in the pharmaceutical sector.
Whether you have a GLP-1 formula ready for scale-up or are exploring the transition to oral and non-injectable formulations, this session will provide crucial insights on the pathway to rapid commercial scale production. Sign up to secure your spot.
We believe there are five keys critical to the success of a transfer. Key in your email to receive our ebook.
Download our corporate brochure to get an overview of our services and understand how we achieve high yields and great quality with all products we produce.
Learn the 5 factors that separate successful transfers from failed ones. Reduce transfer time and eliminate costly delays.
Your download will begin shortly.